Bret Jensen

Discover how Apellis Pharmaceuticals, Inc. surpasses Q4 expectations with impressive revenue growth and cost reductions. Click for my APLS earnings update.

Tariffs have dominated recent headlines. Read why there are bigger issues in the economy.

Collegium Pharmaceutical, Inc. reported strong Q4 results last week where the company easily beat on the bottom line and grew revenues north of 20%. Read more here.

3 biotech/healthcare stocks under $10 with good prospects. See why they stand out after recent dips. Click here to discover more Biotech/Healthcare stocks.

The chances of stagflation appear to be increasing. Click here to read my top stock picks for how to handle this potential market.

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated CLL patients, click for more on NRIX.

Tariff disputes are causing volatility under the new administration, but investors should have two bigger worries right now. Click for more on the U.S. economy.

Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here to read why AVDL stock is a Buy.

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs. Click for more on BLTE stock now.

Definitive Healthcare, a SaaS-enabled technology solution company, is focused on the healthcare industry. Click here to find out why I rate DH stock a hold.

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn more about LGND stock here.

Liquidia Corporation's litigation battle and upcoming commercial launch of its primary candidate, YUTREPIA, take spotlight. Click to read why LQDA is a Hold.

Ultragenyx Pharmaceutical is a mid-cap biotech firm with a promising pipeline and an optimistic outlook from analysts. Click here to read why RARE is a Hold.

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap biotech stocks are worth a closer look.

LeMaitre Vascular stock has fallen back from recent highs, but still is up just over 65% over the past 12 months. Read why I would not buy the dip in LMAT.

Discover three oversold biotech/biopharma stocks to watch amidst market volatility and the JP Morgan Healthcare event in San Francisco. Read up on our picks on Seeking Alpha.

CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.

Recent market volatility is likely due to investors realizing that Fed Funds rate cuts aren't achieving the intended effects. Read what investors need to know.

Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. What is ahead for Tectonic Therapeutic and its shareholders in 2025?